Positron Corp  

(Public, OTCMKTS:POSC)   Watch this stock  
Find more results for Timothy Rooney�
-0.0003 (-4.62%)
Apr 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.00 - 0.01
Open 0.01
Vol / Avg. 60,100.00/730,158.00
Mkt cap 9.01M
P/E     -
Div/yield     -
EPS 0.00
Shares 1.45B
Beta 1.72
Inst. own 0%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -396.01% -284.01%
Operating margin -209.69% -168.58%
EBITD margin - -160.51%
Return on average assets -212.80% -318.65%
Return on average equity - -
Employees 26 -
CDP Score - -


530 Oakmont Lane
United States - Map
+1-317-5760183 (Phone)
+1-630-5371249 (Fax)

Website links


Positron Corporation (Positron) is a molecular imaging healthcare company providing nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. The Company offers a range of products and services for nuclear imaging community. Through PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Attrius is a PET imaging system optimized for cardiology. Positron�s Attrius provides customers with state-of-the-art imaging technology for the diagnosis and treatment of cardiovascular disease. PosiStar is a clinical, technical and service customer care plan. Positron manufactures and processes radiopharmaceuticals at its cGMP (current good manufacturing practice) and NRC (Nuclear Regulatory Commission) licensed manufacturing facility. In January 2012, Positron acquired Manhattan Isotope Technology LLC. (MIT).

Officers and directors

Patrick G. Rooney Chairman of the Board, Chief Executive Officer
Age: 50
Joseph G. Oliverio President, Director
Age: 43
Corey N. Conn Chief Financial Officer, Director
Age: 50
Charles S. Conroy Chief Operating Officer, Executive Director-Sales and Marketing
Age: 43
Timothy M. Gabel Vice President - Engineering & Service
Age: 43
Scott M. Stiffler General Manager-Pharmaceutical Automation and Product Development
Age: 43
Jason J. Kitten Executive Director-Radioisotopes
Age: 40
Anthony C. Nicholls Independent Director
Age: 65
Sachio Okamura Independent Director
Age: 62